Adoptive immunotherapy is an emerging strategy for FL treatment, aiming to exploit the immune system's natural tendency to attack tumoral cells. AntiCD20 monoclonal antibodies have become the backbone of first line and relapse treatments combined with chemotherapy regimens. Anti-idiotype vaccines are the best developed active immunotherapy strategy, with proven efficacy in patients with FL on first relapse. The other vaccine types (Dentritic cells, proteoliposomal or DNA) are still in preclinical development. Adoptive cell transfer (NK cells, LAK and effector T-lymphocytes), chimeric-antigen receptor (CAR) engineered T-cells and Bi-specific T-cell engaging antibodies (BiTE) for passive immunotherapy remain also experimental approaches, although promising pre-clinical results have recently become available.
The following chapter will summarize FL biology and conventional treatment with immunochemotherapy, with a final section focusing specifically on novel immunotherapy strategies (active and passive) for the treatment of FL.
Total Pages: 325-385 (61)
Purchase Chapter
Book Details